Table 2.
AGENTS | PHASE STUDY | MECHANISM OF ACTION |
---|---|---|
First line | ||
Sorafenib and erlotinib | III | Multi-kinase inhibitor and anti-angiogenic |
Second line | ||
Ramucirumab | II–III | Anti-angiogenic |
Bevacizumab | II | Anti-angiogenic |
Cediranib | I–II | Anti-angiogenic |
Pazopanib | ||
Lenvatinib | ||
Lenalidomide | ||
Axitinib | ||
Gefitinib | I–II | EGFR inhibitor |
Lapatinib | ||
Cetuximab | ||
Everolimus | III | mTOR inhibitor |
Sirolimus | I–II | mTOR inhibitor |
Temsirolimus | ||
Tivatinib | II | Hepatocyte growth factor/c-MET inhibitor |
Cabozantinib | ||
Belinostat | I–II | Histone deacetylase inhibitor |
STA-9090 | I–II | HSP-90 inhibitor |